Pro-Cure intends to commercialise new therapeutic prostate targets in collaboration with leading pharmaceutical companies operating in the prostate cancer field.

Having largely completed the Company’s gene profile programme, Pro-Cure is now engaged in “value development” activities based on molecular biology based target validation and the use of its unique in-house in-vitro and in-vivo prostate cancer models.

Data on specific target sets, together with technical and collaborative support from Pro-Cure, will enable partners to accelerate new opportunities into their development pipeline which it is hoped will lead to new prostate drugs being launched.

In addition, Pro-Cure will also look to exploit the commercialisation of research opportunities in similar fields for which it has the management expertise.

The Company is always willing to talk to potential partners interested in entering into a collaborative research partnership or alliance which could include exclusive access to a particular set of potential drug targets. We would also consider undertaking fee for service work as part of such an alliance.

To discuss potential opportunities please contact Dr Deborah Carter, our Business Development Director.